0%
Print report
Variant interpretation report

NTHL1 c.332A>G, p.Tyr111Cys

NM_002528.7:c.332A>G NP_002519.2:p.(Tyr111Cys) Missense · exon 2 View identifiers
Classification
Uncertain significance

Variant description:

The NTHL1 NM_002528.7:c.332A>G (NP_002519.2:p.(Tyr111Cys)) missense variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About NTHL1

NTHL1 encodes a DNA repair enzyme that recognizes and removes oxidized DNA bases, an early step in the base excision repair pathway that protects the genome from oxidative damage. Germline mutations in NTHL1 cause an inherited predisposition to colorectal tumors and other cancers, and the gene acts as a tumor suppressor. Its role in cancer is complex: while it normally guards against DNA damage, it can also generate lethal double-strand breaks in irradiated cells, and the gene is amplified in a subset of breast and pancreatic tumors.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 1
Pathogenic criteria applied · 1
PM2Moderate
PM2 · moderate

Met at Moderate: gnomAD v4.1 AF is 2.17012e-05 with zero homozygotes, below the 0.0001 PM2 cutoff for extremely low frequency.

Benign criteria applied · 1
BP1Supporting
BP1 · supporting

Met, supporting: established NTHL1 tumor syndrome is caused by biallelic loss-of-function variants, while missense effects are modest and low penetrance.

Recorded classification: Uncertain significance

VUS: PM2 (moderate) and BP1 (supporting) do not satisfy a generic ACMG/AMP pathogenic, likely pathogenic, likely benign, or benign combination.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
35 / 1,612,814 alleles

gnomAD v4.1: 35 / 1,612,814 alleles. Recorded AF 2.17012e-05. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.98502e-05; MAF= 0.00399%, 10/250940 alleles, homozygotes = 0) and has highest observed frequency in the Ashkenazi Jewish population (AF= 9.94629e-05; MAF= 0.00995%, 1/10054 alleles, homozygotes = 0); grpmax FAF= 2.863e-05.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

No screenshot for this evidence
REVEL score
0.409 recorded score

Recorded REVEL score: 0.409. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied
ClinVar submissions
6 reported laboratory submissions

6 Uncertain significance. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: not classified.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 2 met · 10 not met · 12 not assessed · 4 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

Among the requested codon, residue, domain, and missense-mechanism criteria, only BP1 is met at ACMG/AMP 2015 supporting strength.

PS1 and PM5 lack an established pathogenic same-residue comparator; PM1 remains unresolved because domain boundaries and absence of benign variation are not demonstrated; PP2 is not supported because NTHL1 disease is primarily loss-of-function rather than a common missense mechanism.

No VCEP covers NTHL1 in this case, so generic ACMG/AMP 2015 rules govern PS3 and BS3.

The reviewed literature provides no variant-specific functional assay result for NTHL1 c.332A>G (p.(Tyr111Cys)); cohort, in-silico, and general scoring evidence cannot substitute for the required functional study.

PS3 and BS3 are both not_assessed rather than not_met because qualifying damaging or benign functional results are absent, not contradictory.

Population evidence supports PM2 at Moderate strength because the variant is present only at extremely low frequency and has zero observed homozygotes in gnomAD v2.1 and v4.1.

BA1 and BS1 are not met because the gnomAD grpmax FAF values are far below their generic thresholds.

BS2 is not assessed because no individual-level healthy-adult phenotype and age observations are available.

Met · 2

PM2 ModerateACMG_2015Met at Moderate: gnomAD v4.1 AF is 2.17012e-05 with zero homozygotes, below the 0.0001 PM2 cutoff for extremely low frequency. Details ▾Hide ▴
Reasoning

PM2 is met at Moderate strength. No governing VCEP specifies a non-cancer or exome-only population source for this gene, so the available all-comers gnomAD totals are used. The variant is observed at extremely low frequency in gnomAD v2.1 (10/250,940 alleles; AF 3.98502e-05) and gnomAD v4.1 (35/1,612,814 alleles; AF 2.17012e-05), with zero homozygotes in both datasets. The gnomAD v4.1 grpmax FAF is 1.567e-05 and the v2.1 grpmax FAF is 2.863e-05; both are below the supplied generic PM2 cutoff of 0.0001. Because NTHL1 disease is represented in the case evidence as a recessive disorder, the ACMG/AMP PM2 parenthetical for extremely low frequency in recessive disease applies despite the variant's nonzero allele count.

Rule
PM2: Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • Generic ACMG/AMP PM2 cutoff supplied for this case: AF <=0.0001; PM2 permits extremely low frequency when the disorder is recessive.
  • gnomAD v2.1 reports 10/250,940 alleles (AF 3.98502e-05), zero homozygotes, and grpmax FAF 2.863e-05.
  • gnomAD v4.1 reports 35/1,612,814 alleles (AF 2.17012e-05), zero homozygotes, and grpmax FAF 1.567e-05.
  • No VCEP governs NTHL1 in this case, so the all-comers GNOMAD_V2_1 and GNOMAD_V4_1 totals are the applicable default population sources rather than non-cancer subsets.
Sources
BP1 SupportingACMG_2015Met, supporting: established NTHL1 tumor syndrome is caused by biallelic loss-of-function variants, while missense effects are modest and low penetrance. Details ▾Hide ▴
Reasoning

The variant is missense. The available gene-level disease evidence identifies NTHL1's established germline tumor syndrome with biallelic loss-of-function variants, whereas the large case-control study characterizes heterozygous missense effects as modest-to-low penetrance and not clinically actionable in isolation. This supports the BP1 pattern that disease in this gene is primarily associated with truncating loss-of-function variants rather than missense variants.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Evidence considered
  • Li et al. 2021 (PMID:33980861), Introduction: carriers of bi-allelic loss-of-function variants in NTHL1 are predisposed to colorectal adenomatous polyposis, colorectal cancer, and a multi-tumor syndrome.
  • Li et al. 2021 (PMID:33980861), Discussion: biallelic loss is the established high-risk mechanism, while heterozygous missense variants are associated with rare, deleterious, modest-to-low penetrance effects that are not clinically actionable in isolation.
Sources

Not met · 10 · evaluated, threshold not reached

PS1 ACMG_2015Not met: ClinVar records p.Tyr111Cys as uncertain significance, with no established pathogenic same-amino-acid substitution identified. Details ▾Hide ▴
Reasoning

The variant is NP_002519.2:p.(Tyr111Cys), but the available exact ClinVar record classifies it as uncertain significance and provides no previously established pathogenic variant with the same amino-acid change. No evidence establishes a pathogenic Tyr111 missense substitution independent of nucleotide change.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.
Evidence considered
  • ClinVar variation 647438, exact record NM_002528.7(NTHL1):c.332A>G (p.Tyr111Cys): classification uncertain significance; six clinical laboratories; no expert-panel submission.
  • No cited paper in the available variant-specific literature mentions p.Tyr111Cys or establishes a pathogenic variant producing the same amino-acid change.
Sources
PS4 ACMG_2015Not met: the available case-control study found aggregate NTHL1 missense enrichment, but no c.332A>G carrier counts, OR, or 95% CI were reported. Details ▾Hide ▴
Reasoning

PS4 is not met. PMID:33980861 is a genuine case-control study (27,421 breast cancer cases and 19,759 controls) and reports aggregate enrichment of NTHL1 missense variants, but the exact NM_002528.7:c.332A>G (p.Tyr111Cys) variant is not mentioned and no carrier counts for this variant are provided. Therefore a variant-specific case-control comparison cannot be made: no variant-specific OR or 95% CI is available, so the required comparison to the ACMG/AMP threshold OR >5.0 with a confidence interval excluding 1.0 cannot be formed. The other literature-pass leads for PS4 (PMID:25394175 and PMID:32239880) do not provide verified variant-specific case-control evidence; PMID:25394175 does not mention NTHL1 or the variant, while PMID:32239880 has no usable abstract/full-text extraction in this case.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • Li et al. 2021 (PMID:33980861): ten international breast cancer case-control cohorts included 27,421 cases and 19,759 controls; the exact c.332A>G/p.Tyr111Cys variant was not mentioned, so no variant-specific OR or 95% CI could be computed.
  • PMID:33980861 reports aggregate NTHL1 missense-variant enrichment, not prevalence of this exact variant; aggregate gene-level enrichment cannot establish PS4 for the variant.
  • PMID:25394175 was checked and does not mention NTHL1 or NM_002528.7:c.332A>G/p.(Y111C).
  • PMID:32239880 was listed as a PS4 literature lead, but the available case packet contains no verified abstract or full-text finding for the exact variant.
  • Numeric rule check: the governing ACMG/AMP comparison is OR > 5.0 with a confidence interval excluding 1.0; no variant-specific OR/CI value was available, so no substituted inequality can be evaluated.
Still missing
  • A variant-specific affected-case and unaffected-control carrier count, or a variant-specific OR with 95% CI, is unavailable.
Sources
PM5 ACMG_2015Not met: no different pathogenic missense change at Tyr111 was identified, and the exact variant itself is classified as uncertain significance. Details ▾Hide ▴
Reasoning

The available same-residue review found no comparator candidates at Tyr111 and no different missense change at residue 111 that was established as pathogenic. The exact ClinVar record for p.Tyr111Cys is uncertain significance, not evidence of a pathogenic alternate missense at the residue.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.
Evidence considered
  • ClinVar variation 647438, exact p.Tyr111Cys record: uncertain significance with six clinical laboratories and no expert-panel submission.
  • Same-residue comparator review for Tyr111 found zero candidates; no pathogenic alternate missense at residue 111 was available for PM5.
Sources
PP2 ACMG_2015Not met: NTHL1 disease is established primarily through biallelic loss of function, while heterozygous missense effects are described as modest or low penetrance. Details ▾Hide ▴
Reasoning

The PP2 mechanism requirement is not supported. NTHL1's established high-risk germline syndrome is associated with biallelic loss-of-function variants, while PMID:33980861 describes heterozygous missense effects as modest or low penetrance rather than a common disease mechanism. The available evidence also does not establish a low rate of benign missense variation sufficient to satisfy the other conjunctive PP2 requirement.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
  • Li et al. 2021 (PMID:33980861), Introduction and Discussion: biallelic NTHL1 loss-of-function variants cause the established tumor syndrome; heterozygous missense variants were associated with a modest-to-low penetrance effect.
  • Li et al. 2021 (PMID:33980861), Results: missense variants were enriched in cases (75, 1.50%) versus controls (47, 0.98%), OR 1.54, 95% CI 1.05-2.27, but this does not establish missense variants as the common mechanism of the established NTHL1 syndrome.
Sources
PP3 ACMGNot met: missense REVEL is 0.409, below the PP3 supporting threshold of >= 0.644. Details ▾Hide ▴
Reasoning

NM_002528.7:c.332A>G is a missense variant producing NP_002519.2:p.(Tyr111Cys), so the applicable generic PP3 path is REVEL only; SpliceAI is not used for a missense PP3 assessment. REVEL is 0.409, which is below the supporting PP3 threshold of >= 0.644. BayesDel has no established generic ACMG-strength calibration and is not evidence for PP3. Therefore PP3 is not met at its ACMG/AMP 2015 supporting strength.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant. ... PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Consequence classification: missense, NM_002528.7:c.332A>G -> NP_002519.2:p.(Tyr111Cys).
  • Applicable predictor path: missense variant -> REVEL only; the SpliceAI result is not used for PP3/BP4 in this missense situation.
  • REVEL score: 0.409; this is below the PP3 supporting cutoff >= 0.644 from the ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997).
  • BayesDel score -0.113504 is not used because no generic ACMG-strength calibration is established for BayesDel.
Sources
PP5 ACMG_2015Not met: ClinVar has zero expert-panel classifications for this exact variant, and all six laboratory submissions report Uncertain significance. Details ▾Hide ▴
Reasoning

PP5 is not met. The exact ClinVar record for NM_002528.7:c.332A>G (p.Tyr111Cys) has six clinical-laboratory submissions, all classified as Uncertain significance, and zero expert-panel submissions. No exact-variant ClinVar expert-panel Pathogenic or Likely pathogenic classification is present. The cited literature includes general ACMG guidance and non-variant-specific or non-supportive papers, not a verified reputable-source report of this exact variant as pathogenic.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 647438, exact variant NM_002528.7(NTHL1):c.332A>G (p.Tyr111Cys): six clinical-laboratory submissions are Uncertain significance and expert_panel_submissions = 0.
  • Generic PP5 gate: an exact-variant ClinVar expert-panel Pathogenic/Likely pathogenic classification is required; ordinary laboratory submissions and aggregate labels do not trigger PP5.
  • PMID:25741868 is a general ACMG/AMP standards paper and does not report this variant as pathogenic.
  • PMID:33980861 does not mention the exact variant; PMID:25394175 does not mention NTHL1 or the variant; PMID:32239880 has no verified variant-specific extraction available.
Sources
BA1 ACMG_2015Not met: grpmax FAF is 2.863e-05 in gnomAD v2.1 and 1.567e-05 in v4.1, both far below the 0.05 BA1 threshold. Details ▾Hide ▴
Reasoning

BA1 is not met. Under the generic ACMG/AMP default, BA1 requires an allele frequency of at least 0.05. The relevant filtering allele frequencies are far below this threshold: gnomAD v2.1 grpmax FAF 2.863e-05 and gnomAD v4.1 grpmax FAF 1.567e-05. The highest observed ancestry groups are Ashkenazi Jewish, with 1/10,054 alleles in v2.1 and 2/29,604 alleles in v4.1; both populations exceed the 2,000-observed-allele minimum. No population-frequency evidence supports a stand-alone benign call, and the available ClinVar consensus is uncertain rather than a pathogenic consensus that would create a frequency-classification conflict.

Rule
BA1: Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • Generic ACMG/AMP BA1 default threshold: allele frequency >=0.05.
  • gnomAD v2.1 reports 10/250,940 total alleles, AF 3.98502e-05, zero homozygotes, and grpmax FAF 2.863e-05; the highest observed ancestry group is Ashkenazi Jewish at 1/10,054 alleles.
  • gnomAD v4.1 reports 35/1,612,814 total alleles, AF 2.17012e-05, zero homozygotes, and grpmax FAF 1.567e-05; the highest observed ancestry group is Ashkenazi Jewish at 2/29,604 alleles.
  • The qualifying ancestry-group allele counts exceed 2,000 observed alleles, so the FAF comparison is not based on a small isolate population.
Sources
BS1 ACMG_2015Not met: the highest qualifying grpmax FAF is 2.863e-05, far below the generic 0.01 BS1 threshold. Details ▾Hide ▴
Reasoning

BS1 is not met. The generic default threshold supplied for BS1 is >=0.01, and the required filtering allele-frequency measure is the gnomAD grpmax FAF rather than a popmax point estimate. The gnomAD v2.1 grpmax FAF is 2.863e-05 and the gnomAD v4.1 grpmax FAF is 1.567e-05, both well below 0.01. The highest observed ancestry groups have adequate allele counts (Ashkenazi Jewish: 1/10,054 in v2.1 and 2/29,604 in v4.1), so the result is not an isolate-population popmax artifact. These frequencies do not approach a level requiring a disorder-specific maximum-credible-frequency calculation to reject the generic BS1 default; no BS1 evidence is established.

Rule
BS1: Allele frequency is greater than expected for the disorder.
Evidence considered
  • Generic ACMG/AMP BS1 default threshold: allele frequency >=0.01; the criterion concerns an allele frequency greater than expected for the disorder.
  • gnomAD v2.1 reports grpmax FAF 2.863e-05, with the highest observed ancestry-group point estimate in Ashkenazi Jewish at 1/10,054 alleles.
  • gnomAD v4.1 reports grpmax FAF 1.567e-05, with the highest observed ancestry-group point estimate in Ashkenazi Jewish at 2/29,604 alleles.
  • The FAF values, rather than popmax point estimates, are used for the threshold decision; both available FAF values are orders of magnitude below 0.01.
Sources
BP4 ACMGNot met: missense REVEL is 0.409, above the BP4 supporting threshold of <= 0.29. Details ▾Hide ▴
Reasoning

NM_002528.7:c.332A>G is a missense variant producing NP_002519.2:p.(Tyr111Cys), so the applicable generic BP4 path is REVEL only; SpliceAI is not used for a missense BP4 assessment. REVEL is 0.409, which is above the supporting BP4 threshold of <= 0.29. The result is therefore not a qualifying benign/low-impact REVEL result, and the SpliceAI score cannot substitute for it. BayesDel has no established generic ACMG-strength calibration and is not evidence for BP4. Therefore BP4 is not met at its ACMG/AMP 2015 supporting strength.

Rule
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc). ... Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant. ... BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Consequence classification: missense, NM_002528.7:c.332A>G -> NP_002519.2:p.(Tyr111Cys).
  • Applicable predictor path: missense variant -> REVEL only; the SpliceAI result is not used for PP3/BP4 in this missense situation.
  • REVEL score: 0.409; this is above the BP4 supporting cutoff <= 0.29 from the ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997).
  • BayesDel score -0.113504 is not used because no generic ACMG-strength calibration is established for BayesDel.
Sources
BP6 ACMG_2015Not met: no exact-variant ClinVar expert-panel Benign/Likely benign classification exists, while all six laboratory submissions are Uncertain significance. Details ▾Hide ▴
Reasoning

BP6 is not met. The exact ClinVar record for NM_002528.7:c.332A>G (p.Tyr111Cys) has zero expert-panel submissions and all six clinical-laboratory submissions are Uncertain significance. No exact-variant ClinVar expert-panel Benign or Likely benign classification is present, and no verified reputable-source benign report was identified.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 647438, exact variant NM_002528.7(NTHL1):c.332A>G (p.Tyr111Cys): six clinical-laboratory submissions are Uncertain significance and expert_panel_submissions = 0.
  • Generic BP6 gate: an exact-variant ClinVar expert-panel Benign/Likely benign classification is required; ordinary laboratory submissions and aggregate labels do not trigger BP6.
  • PMID:25394175 does not mention NTHL1 or the variant, and PMID:32239880 has no verified variant-specific extraction available.
Sources

Not assessed · 12 · no assessment recorded

PS2 ACMG_2015Not assessed: no documented affected proband with confirmed maternity and paternity, parental genotypes, and absent family history is available for this variant. Details ▾Hide ▴
Reasoning

No case-specific evidence was identified documenting a de novo occurrence of NM_002528.7:c.332A>G (NP_002519.2:p.(Tyr111Cys)) in an affected individual. The available records do not establish both maternity and paternity, do not describe parental genotypes, and do not document absence of a family history; therefore the PS2 definition cannot be assessed.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • The case evidence identifies the variant as NM_002528.7:c.332A>G (NP_002519.2:p.(Tyr111Cys)) but contains no proband-level de novo report or parental-testing results.
  • PMID:33980861 was reviewed for variant-specific clinical and familial evidence; its extraction states that the exact variant was not mentioned and provides no segregation data.
Still missing
  • Affected-proband report with the exact variant
  • Documented confirmation of both maternity and paternity
  • Parental genotype results showing the variant absent in both parents
  • Documented absence of family history
Sources
PS3 ACMG_2015Not assessed: no variant-specific functional assay or damaging-effect readout is reported for NTHL1 p.(Tyr111Cys), so PS3 Strong cannot be applied. Details ▾Hide ▴
Reasoning

NM_002528.7:c.332A>G (NP_002519.2:p.(Tyr111Cys)) is a missense variant, but the reviewed evidence contains no variant-specific in vitro or in vivo functional assay result demonstrating a damaging effect. PMID:33980861 evaluated NTHL1 variants in large case-control cohorts and explicitly did not report functional assay results for p.(Tyr111Cys); PMID:26467025 describes a general clinical-laboratory scoring dataset and does not mention this variant. No validated, reproducible assay result, assay control data, or biologically relevant experimental readout is available to calibrate PS3 at the required 2015 Strong strength. PS3 is therefore not_assessed, not not_met, because the evidence gap reflects absence of qualifying functional data rather than a negative functional result.

Rule
PS3: Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product. ... Note: Functional studies that have been validated and shown to be reproducible and robust in a clinical diagnostic laboratory setting are considered the most well-established.
Evidence considered
  • PMID:33980861, paper_extracts finding: the exact c.332A>G/p.(Tyr111Cys) variant was not explicitly mentioned and the study did not provide functional assay results for p.(Tyr111Cys).
  • PMID:33980861, Discussion, final paragraph (Summary): "The data suggest that NTHL1 may be associated with a modest increase in breast cancer risk that would not be considered clinically actionable in isolation under current clinical guidelines but could be relevant when combined with additional risk factors." This is clinical association evidence, not a variant-specific functional assay.
  • PMID:26467025, Materials and Methods, Data Collection and Storage: the study covered 11,894 variants in 338 genes and used prediction, population-frequency, co-occurrence, segregation, and functional-study data, but the paper does not mention NTHL1 c.332A>G or p.Y111C and provides no assay result for this variant.
Still missing
  • A variant-specific, well-established in vitro or in vivo assay measuring NTHL1 function is needed.
  • Assay controls, reproducibility, and a biologically relevant damaging-effect readout are unavailable.
Sources
PM1 ACMG_2015Not assessed: an Endonuclease III domain is reported, but residue boundaries and the required absence of benign variation at Tyr111 are not established. Details ▾Hide ▴
Reasoning

PMID:33980861 reports enrichment of missense variants in the NTHL1 Endonuclease III domain, but the available evidence does not define the domain's residue boundaries sufficiently to confirm that Tyr111 lies within it, and it does not establish the required absence of benign variation for this residue/domain. Cancer Hotspots found no statistically significant hotspot. These unresolved location and benign-variation requirements prevent a defensible PM1 determination.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • Li et al. 2021 (PMID:33980861), Results, paragraph beginning 'In contrast to the LoF variants': missense variants in the NTHL1 Endonuclease III domain were enriched in cases versus controls (187 vs. 95; OR 1.42, 95% CI 1.11-1.82), but no residue boundaries for the domain were supplied in the extracted evidence.
  • Cancer Hotspots query NTHL1 Y111: no result; evidence sentence states that the variant does not lie in a statistically significant hotspot.
Still missing
  • A source defining the Endonuclease III domain boundaries on NP_002519.2 is needed to verify whether residue 111 is inside the domain.
  • Evidence that the relevant domain or residue lacks benign variation is needed.
Sources
PM3 ACMG_2015Not assessed: no report documents a pathogenic NTHL1 variant in trans with c.332A>G or provides parental/offspring phase testing. Details ▾Hide ▴
Reasoning

The available evidence does not document an affected proband carrying NM_002528.7:c.332A>G with a known pathogenic NTHL1 variant in trans, and no parental or offspring testing establishes phase. The reviewed NTHL1 cohort study did not mention c.332A>G or p.(Tyr111Cys) and provided no variant-specific clinical, segregation, or phase data. Therefore PM3 cannot be assessed.

Rule
PM3: For recessive disorders, detected in trans with a pathogenic variant ... Note: This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • Li et al. 2021 (PMID:33980861) evaluated NTHL1 variants in 47,180 participants but did not mention c.332A>G or p.(Tyr111Cys) and reported no variant-specific clinical, segregation, or phase data for this variant.
  • No case evidence in the reviewed materials establishes a pathogenic NTHL1 allele in trans with NM_002528.7:c.332A>G.
Still missing
  • Affected-proband observation with a known pathogenic NTHL1 variant is needed.
  • Parental or offspring testing establishing trans phase is needed.
Sources
PM6 ACMG_2015Not assessed: no affected-proband report documents this variant as assumed de novo without confirmed maternity and paternity testing. Details ▾Hide ▴
Reasoning

No case-specific evidence was identified documenting an assumed de novo occurrence of NM_002528.7:c.332A>G (NP_002519.2:p.(Tyr111Cys)) without confirmed parental testing. The available records do not provide a proband-level report or indicate which, if any, parent was tested; therefore PM6 cannot be assessed.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • The case evidence contains no proband-level de novo observation, parental genotype information, or statement that the variant was assumed de novo.
  • PMID:33980861 was reviewed for variant-specific clinical and familial evidence; its extraction states that the exact variant was not mentioned and provides no segregation data.
Still missing
  • Affected-proband report with the exact variant
  • Evidence that the variant was considered de novo
  • Parental-testing details showing that maternity and/or paternity confirmation was unavailable
Sources
PP1 ACMG_2015Not assessed: no affected relatives, genotype results, or informative meioses demonstrate co-segregation of this variant with disease. Details ▾Hide ▴
Reasoning

No case-specific family data were identified showing NM_002528.7:c.332A>G (NP_002519.2:p.(Tyr111Cys)) co-segregating with disease in affected relatives. The available records provide no affected relatives, genotypes, meioses, or phenotype-linked segregation count, so PP1 cannot be assessed at supporting or a stronger 2015 strength.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease. ... Note: May be used as stronger evidence with increasing segregation data.
Evidence considered
  • The case evidence contains no pedigree, affected-relative genotype, meiosis count, or variant-specific co-segregation result.
  • PMID:33980861 was reviewed for variant-specific familial evidence; its extraction states that the exact variant was not mentioned and provides no segregation data.
Still missing
  • Pedigree and phenotype information for affected relatives
  • Genotypes of affected and informative unaffected relatives
  • Number of informative meioses and co-segregating transmissions
  • Confirmation that the gene is definitively associated with the family disease
Sources
PP4 ACMG_2015Not assessed: no patient phenotype, family history, or disease-specific clinical diagnosis is provided for evaluating PP4. Details ▾Hide ▴
Reasoning

PP4 cannot be assessed from the available evidence. The case materials identify NM_002528.7:c.332A>G (p.Tyr111Cys) in NTHL1 but do not provide the patient's phenotype, family history, or a clinical diagnosis sufficiently specific for a disease with a single genetic etiology. The reviewed literature also does not provide a verified phenotype description for this exact variant.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Evidence considered
  • Case materials provide the NTHL1 variant identity and missense consequence but no patient phenotype or family history.
  • The reviewed variant-specific literature does not document a verified phenotype for c.332A>G/p.Tyr111Cys.
Still missing
  • Patient phenotype and family-history details, including the diagnosed disease and its specificity, are needed.
Sources
BS2 ACMG_2015Not assessed: gnomAD reports zero homozygotes but provides no individual healthy-adult phenotype or age information required for BS2. Details ▾Hide ▴
Reasoning

BS2 cannot be assessed from the available evidence. The criterion requires observation in a healthy adult individual, with the relevant genotype for a recessive, dominant, or X-linked disorder and full penetrance expected at an early age. gnomAD v2.1 and v4.1 report zero homozygotes, but they do not provide individual-level healthy-adult phenotype, age, follow-up, or disease-penetrance information, and absence of homozygotes is not an observation that the variant is present in a healthy adult. No qualifying individual clinical or research observations are supplied.

Rule
BS2: Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v2.1 reports zero homozygotes and gnomAD v4.1 reports zero homozygotes, but neither source supplies individual-level phenotype or age/follow-up data.
  • No qualifying healthy-adult carrier or homozygote observation was identified in the supplied evidence.
Still missing
  • Individual-level observations are needed showing the variant in a healthy adult with documented age, phenotype, genotype, and relevant inheritance context.
Sources
BS3 ACMG_2015Not assessed: no variant-specific functional assay demonstrates preserved NTHL1 protein function or splicing, so BS3 Strong cannot be applied. Details ▾Hide ▴
Reasoning

NM_002528.7:c.332A>G (NP_002519.2:p.(Tyr111Cys)) is a missense variant, but the reviewed evidence contains no variant-specific in vitro or in vivo functional assay result showing no damaging effect on protein function or splicing. PMID:33980861 did not report functional assay results for p.(Tyr111Cys), and PMID:26467025 does not mention this variant or provide a variant-specific benign functional readout. Because no assay result, appropriate controls, reproducibility data, or biologically relevant normal-function measurement is available, BS3 cannot reach the ACMG/AMP 2015 Strong strength. BS3 is therefore not_assessed rather than not_met; no negative functional study was identified.

Rule
BS3: Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • PMID:33980861, paper_extracts finding: the exact c.332A>G/p.(Tyr111Cys) variant was not explicitly mentioned and the study did not provide functional assay results for p.(Tyr111Cys).
  • PMID:33980861, experimental context: ten international breast cancer case-control studies assessed NTHL1 variant enrichment, functional-domain location, population rarity, and in-silico predictions; this does not provide a variant-specific normal-function assay for p.(Tyr111Cys).
  • PMID:26467025, paper_extracts finding: the paper does not explicitly mention NTHL1, c.332A>G, NP_002519.2:p.(Y111C), or p.Y111C and therefore provides no variant-specific functional assay result.
Still missing
  • A variant-specific, well-established in vitro or in vivo assay showing no damaging effect on NTHL1 protein function or splicing is needed.
  • Assay controls, reproducibility, and a biologically relevant normal-function readout are unavailable.
Sources
BS4 ACMG_2015Not assessed: no affected relatives are documented as negative for this variant, and no pedigree data permit evaluation of non-segregation. Details ▾Hide ▴
Reasoning

No case-specific family data were identified showing lack of segregation of NM_002528.7:c.332A>G (NP_002519.2:p.(Tyr111Cys)) in affected relatives. The available records provide no affected relatives tested negative for the variant and no phenotype or pedigree information to evaluate phenocopy or multiple-variant explanations; therefore BS4 cannot be assessed.

Rule
Lack of segregation in affected members of a family.
Evidence considered
  • The case evidence contains no affected-relative testing results, non-segregation count, pedigree, or phenotype data.
  • PMID:33980861 was reviewed for variant-specific familial evidence; its extraction states that the exact variant was not mentioned and provides no segregation data.
Still missing
  • Pedigree and phenotype information for affected relatives
  • Genotype results for affected relatives
  • Evidence that affected relatives lack the variant
  • Assessment of phenocopies and possible additional pathogenic variants
Sources
BP2 ACMG_2015Not assessed: no report documents c.332A>G in trans or cis with a pathogenic variant, and no phase data are available. Details ▾Hide ▴
Reasoning

The available evidence does not document NM_002528.7:c.332A>G observed in trans with a pathogenic variant in a fully penetrant dominant NTHL1 disorder, nor in cis with a pathogenic variant in any inheritance pattern. The reviewed NTHL1 cohort study did not mention c.332A>G or p.(Tyr111Cys) and provided no variant-specific clinical, segregation, or phase data. Therefore BP2 cannot be assessed.

Rule
BP2: Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • Li et al. 2021 (PMID:33980861) evaluated NTHL1 variants in 47,180 participants but did not mention c.332A>G or p.(Tyr111Cys) and reported no variant-specific clinical, segregation, or phase data for this variant.
  • No case evidence in the reviewed materials establishes NM_002528.7:c.332A>G in trans or cis with a pathogenic variant.
Still missing
  • A documented pathogenic variant paired with c.332A>G is needed.
  • Testing establishing trans or cis phase is needed.
Sources
BP5 ACMG_2015Not assessed: no documented case links this exact variant with an alternate molecular basis for the disease. Details ▾Hide ▴
Reasoning

BP5 cannot be assessed because the available case evidence does not identify a patient carrying NM_002528.7:c.332A>G (p.Tyr111Cys) with an alternate molecular basis for the disease. The case packet contains no documented alternate pathogenic molecular diagnosis for such a case.

Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • No exact-variant case with an alternate molecular basis is documented in the available case evidence or verified literature extracts.
Still missing
  • A case report or clinical record documenting the exact variant together with an alternate molecular diagnosis is needed.
Sources
Not applicable · 4· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_002528.7:c.332A>G in NTHL1 is a missense substitution predicted to produce NP_002519.2:p.(Tyr111Cys). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for NTHL1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_002528.7:c.332A>G in NTHL1 is a missense substitution predicted to produce NP_002519.2:p.(Tyr111Cys). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for NTHL1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_002528.7:c.332A>G in NTHL1 is a missense substitution predicted to produce NP_002519.2:p.(Tyr111Cys). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for NTHL1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_002528.7:c.332A>G in NTHL1 is a missense substitution predicted to produce NP_002519.2:p.(Tyr111Cys). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for NTHL1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
NTHL1
Transcript
NM_002528.7
Coding (HGVS c.)
NM_002528.7:c.332A>G
Protein (HGVS p.)
NP_002519.2:p.(Tyr111Cys)
GRCh38
chr16:2046150 T>C
GRCh37
chr16:2096151 T>C
Location and type
Exon 2 · missense
ClinVar
647438

Gene diagram

Every interpreted variant in NTHL1, mapped onto the exon structure of NM_002528.7. Select a row to find it on the plot.

NTHL1NM_002528.7
Fetching transcript structure from UCSC…
gnomAD v4.1 35 / 1,612,814 alleles AF 2.17e-05 · 0 homozygotes · FAF 1.57e-05
gnomAD v2.1 10 / 250,940 alleles AF 3.99e-05 · 0 homozygotes · FAF 2.86e-05
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 2.2e-05 · 35 / 1,612,814 alleles · 0 hom · FAF 1.6e-05
Ashkenazi Jewish2 / 29,604 6.8e-05
European (non-Finnish)27 / 1,179,778 2.3e-05
East Asian1 / 44,880 2.2e-05
South Asian2 / 91,090 2.2e-05
Admixed American1 / 59,996 1.7e-05
Remaining individuals1 / 62,456 1.6e-05
European (Finnish)1 / 63,102 1.6e-05
0 alternate alleles recorded in 3 other groups: Amish, Middle Eastern, African/African American.

gnomAD v2.1

AF 4e-05 · 10 / 250,940 alleles · 0 hom · FAF 2.9e-05
Ashkenazi Jewish1 / 10,054 9.9e-05
European (non-Finnish)7 / 113,306 6.2e-05
South Asian1 / 30,616 3.3e-05
Admixed American1 / 34,574 2.9e-05
0 alternate alleles recorded in 4 other groups: African/African American, East Asian, European (Finnish), Remaining individuals.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 2.17012e-05; MAF= 0.00217%, 35/1612814 alleles, homozygotes = 0) and has highest observed frequency in the Ashkenazi Jewish population (AF= 6.75584e-05; MAF= 0.00676%, 2/29604 alleles, homozygotes = 0); grpmax FAF= 1.567e-05.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.98502e-05; MAF= 0.00399%, 10/250940 alleles, homozygotes = 0) and has highest observed frequency in the Ashkenazi Jewish population (AF= 9.94629e-05; MAF= 0.00995%, 1/10054 alleles, homozygotes = 0); grpmax FAF= 2.863e-05.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat +213 bp
0.007
SpliceAI acceptor gainat +241 bp
0.002
SpliceAI donor lossat -22 bp
0.001
SpliceAI donor gainat +130 bp
0.017
Pangolin splice lossmagnitude shown
-0.021
Pangolin splice gain
0.013

Other predictors

REVEL
0.409
BayesDel
-0.114

How the predictions were used

PP3 ACMGNot met: missense REVEL is 0.409, below the PP3 supporting threshold of >= 0.644. Details ▾Hide ▴
Reasoning

NM_002528.7:c.332A>G is a missense variant producing NP_002519.2:p.(Tyr111Cys), so the applicable generic PP3 path is REVEL only; SpliceAI is not used for a missense PP3 assessment. REVEL is 0.409, which is below the supporting PP3 threshold of >= 0.644. BayesDel has no established generic ACMG-strength calibration and is not evidence for PP3. Therefore PP3 is not met at its ACMG/AMP 2015 supporting strength.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant. ... PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Consequence classification: missense, NM_002528.7:c.332A>G -> NP_002519.2:p.(Tyr111Cys).
  • Applicable predictor path: missense variant -> REVEL only; the SpliceAI result is not used for PP3/BP4 in this missense situation.
  • REVEL score: 0.409; this is below the PP3 supporting cutoff >= 0.644 from the ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997).
  • BayesDel score -0.113504 is not used because no generic ACMG-strength calibration is established for BayesDel.
Sources
BP4 ACMGNot met: missense REVEL is 0.409, above the BP4 supporting threshold of <= 0.29. Details ▾Hide ▴
Reasoning

NM_002528.7:c.332A>G is a missense variant producing NP_002519.2:p.(Tyr111Cys), so the applicable generic BP4 path is REVEL only; SpliceAI is not used for a missense BP4 assessment. REVEL is 0.409, which is above the supporting BP4 threshold of <= 0.29. The result is therefore not a qualifying benign/low-impact REVEL result, and the SpliceAI score cannot substitute for it. BayesDel has no established generic ACMG-strength calibration and is not evidence for BP4. Therefore BP4 is not met at its ACMG/AMP 2015 supporting strength.

Rule
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc). ... Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant. ... BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Consequence classification: missense, NM_002528.7:c.332A>G -> NP_002519.2:p.(Tyr111Cys).
  • Applicable predictor path: missense variant -> REVEL only; the SpliceAI result is not used for PP3/BP4 in this missense situation.
  • REVEL score: 0.409; this is above the BP4 supporting cutoff <= 0.29 from the ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997).
  • BayesDel score -0.113504 is not used because no generic ACMG-strength calibration is established for BayesDel.
Sources
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_002528.7:c.332A>G in NTHL1 is a missense substitution predicted to produce NP_002519.2:p.(Tyr111Cys). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for NTHL1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.02). REVEL score = 0.409. BayesDel score = -0.113504.

5 paper records listed. 1 cited in the classification. None of the listed paper records explicitly indicates that the variant is named.

Cited in the classification

  • Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects.
    Li N et al. · 2021 May 12
    Li et al. evaluated NTHL1 variants in 47,180 participants from ten international breast-cancer case-control cohorts. Missense variants were enriched in cases, including within the Endonuclease III domain, but the authors characterize heterozygous missense effects as modest-to-low penetrance; the established high-risk syndrome is associated with biallelic loss of function.
    → BP1 · supporting Does not name this variant
    PMID 33980861 ↗
    Source detail
    While the detected missense variants were distributed across the whole gene (Supplementary Table 6), there was an enrichment of missense variants in the cases compared to controls in the Endonuclease III domain of NTHL1 (187 vs. 95, OR 1.42, 95% CI: 1.11–1.82)

    Location Results, paragraph beginning 'In contrast to the LoF variants'

    Context Ten international breast-cancer case-control studies comprising 27,421 cases and 19,759 controls; coding-region and exon-intron-boundary sequencing with missense enrichment analyses by domain and in-silico/rareness filters.

Other recorded publications

  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    Richards S et al. · 2015
    This is the general ACMG/AMP standards paper. It does not mention NTHL1, c.332A>G, or p.(Y111C), and therefore supplies the governing PS4, PP4, PP5, BP5, and BP6 definitions but no variant-specific evidence.
    Does not name this variant
    PMID 25741868 ↗
  • A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders.
    Karbassi I et al. · 2016
    This paper describes a general rules-based pathogenicity-scoring system applied to variants across 338 genes and does not explicitly mention NTHL1 c.332A>G, NP_002519.2:p.(Y111C), or p.Y111C. It provides no variant-specific functional assay result for this case.
    Does not name this variant
    PMID 26467025 ↗
    Quoted passage
    Over 16,500 pathogenicity assessments on 11,894 distinct variants in 338 genes causing neurological, endocrine, and nephrotic genetic disorders were performed on the sequencing data.

    Materials and Methods, Data Collection and Storage

  • A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.
    Hampel H et al. · 2015
    This cancer-genetic referral guideline does not mention NTHL1 or NM_002528.7:c.332A>G (p.Tyr111Cys) and provides no variant-specific phenotype, case-control, or pathogenic/benign classification evidence.
    Does not name this variant
    PMID 25394175 ↗
  • NTHL1 Tumor Syndrome.
    Adam MP et al. · 1993
    The literature-pass packet listed this NTHL1 Tumor Syndrome reference as a PS4/PP5 lead, but no verified abstract or full-text extraction for the exact c.332A>G/p.Tyr111Cys variant is available in the case materials; it cannot support a criterion decision.
    Does not name this variant
    PMID 32239880 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 2.17012e-05; MAF= 0.00217%, 35/1612814 alleles, homozygotes = 0) and has highest observed frequency in the Ashkenazi Jewish population (AF= 6.75584e-05; MAF= 0.00676%, 2/29604 alleles, homozygotes = 0); grpmax FAF= 1.567e-05.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.98502e-05; MAF= 0.00399%, 10/250940 alleles, homozygotes = 0) and has highest observed frequency in the Ashkenazi Jewish population (AF= 9.94629e-05; MAF= 0.00995%, 1/10054 alleles, homozygotes = 0); grpmax FAF= 2.863e-05.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Uncertain significance (6 clinical laboratories). (ClinVarID = 647438)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.02). REVEL score = 0.409. BayesDel score = -0.113504.

Functional

OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: not classified.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.